Personal information

No personal information available

Biography

Expertise in CAR T cell therapy and related technologies.
Interested in cell therapy that can improve cancer treatment.

Activities

Collapse all

Employment (2)

Lentigen Technology (United States): Gaithersburg, Maryland, US

2015-01-12 to 2022-02-22 | Senior Research Scientist I (R&D)
Employment
Source: Self-asserted source
Ying Xiong

National Institute of Dental and Craniofacial Research: Bethesda, MD, US

2009-01-01 to 2012-07-01 | Post Doctoral (NIDCR)
Employment
Source: Self-asserted source
Ying Xiong

Education and qualifications (1)

The Ohio State University: Columbus, Ohio, US

2003-09-01 to 2008-03-15 | Ph.D (Chemical Engineering)
Education
Source: Self-asserted source
Ying Xiong

Works (8)

Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models

Molecular Therapy
2021-09 | Journal article
DOI: 10.1016/j.ymthe.2021.05.006
Contributors: Brian Webster; Ying Xiong; Peirong Hu; Darong Wu; Leah Alabanza; Rimas J. Orentas; Boro Dropulic; Dina Schneider
Source: check_circle
Crossref

Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models

Science Translational Medicine
2021-03-24 | Journal article
DOI: 10.1126/scitranslmed.abc6401
Contributors: Dina Schneider; Ying Xiong; Darong Wu; Peirong Hu; Leah Alabanza; Brittany Steimle; Hasan Mahmud; Kim Anthony-Gonda; Winfried Krueger; Zhongyu Zhu et al.
Source: check_circle
Crossref

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.

Frontiers in immunology
2020-08-07 | Journal article
DOI: 10.3389/fimmu.2020.01941
PMID: 32849651
PMC: PMC7427107
Source: Self-asserted source
Ying Xiong

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.

Frontiers in oncology
2018-11-22 | Journal article
DOI: 10.3389/fonc.2018.00539
PMID: 30524966
PMC: PMC6262782
Source: Self-asserted source
Ying Xiong

Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes.

Leukemia & lymphoma
2018-05-09 | Journal article
DOI: 10.1080/10428194.2018.1464159
PMID: 29741135
PMC: PMC6226347
Source: Self-asserted source
Ying Xiong

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

Journal for immunotherapy of cancer
2017-05-16 | Journal article
DOI: 10.1186/s40425-017-0246-1
PMID: 28515942
PMC: PMC5433150
Source: Self-asserted source
Ying Xiong

Polyreactive antibodies plus complement enhance the phagocytosis of cells made apoptotic by UV-light or HIV.

Scientific reports
2013-01-01 | Journal article
DOI: 10.1038/srep02271
PMID: 23881356
PMC: PMC3721073
Source: Self-asserted source
Ying Xiong

A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation.

Experimental hematology
2007-08-13 | Journal article
DOI: 10.1016/j.exphem.2007.06.015
PMID: 17697744
PMC: PMC2094009
Source: Self-asserted source
Ying Xiong
How many people are using ORCID?